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Transplantation
Alwi Shatry, Robert B. LevyHost antidonor effector T cells represent a major barrier to the successful engraftment of allogeneic donor
hematopoietic progenitor and stem cells. Here, administration of a complex of IL-2 and anti-IL 2 antibodies
(IAC) significantly enhanced donor chimerism early as well as long-term engraftment following reduced-in-
tensity conditioning (RIC) and allogeneic major histocompatibility complex (MHC)-matched hematopoietic
cell transplantion (HCT). Timing of administration of this complex was crucial: administration of IAC post-
HCT more efficiently facilitated marrow engraftment than pre-HCT treatment. Donor chimerism persisted
to .6 months post-HCT. Importantly, this approach clearly suppressed the emergence of host antidonor
CD8 T cells 2 to 3 weeks post-HCT as assessed by tetramer staining. Following in vivo reactivation of
IAC-treated and control recipients at .5 months post-HCTwith donor antigen, only PBS-treated control
marrow allograft recipients respondedwith tetramer-binding CD8 cells. In total, the present findings support
the notion that the transient activation and expansion of host Tregs in situ post-HCT can be explored as
a new approach to regulate host alloreactivity posttransplant. Interestingly, direct stimulation of recipient
Treg cells in RIC recipients obviated a requirement for exogenous Treg cell transfusion in this model and
may represent a viable alternative to, and/or complement the adaptive transfer of Treg populations in clinical
HCT.
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The regulatory functions of CD41 CD251 FoxP31
cells (Tregs) in maintaining peripheral tolerance [1,2] to
self-antigens has led to studies investigating their use in
inhibiting alloreactive T cell responses following alloge-
neic marrow transplantation [3-5]. Naturally occurring
Tregs can induce transplantation tolerance in mice [4-
6]. A significant reduction of lethal graft-versus-host dis-
ease (GVHD) has been observed following injection ofepartment ofMicrobiology and Immunology, University
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6/j.bbmt.2009.03.011freshly isolated or ex vivo activated Tregs [5,7,8]. Tregs
have been reported to act in an antigen-specific manner
[9-13] andareknowntopreventCD8Tcell-mediated al-
lograft rejection [10].Notably, most existing experimen-
tal models of allogeneic hematopoietic cell
transplantation (HCT) utilizing Tregs have employed
the collection, purification, and transfer of exogenous
populations of donor CD41 CD251 Treg cells
[12,14,15]. Recent studies from our group have reported
the presence and persistence of host CD41 CD251
FoxP31 regulatory cells following reduced-intensity
conditioning (RIC) andT cell-depletedHCT [16]. Boy-
man and colleagues [17] demonstrated that mouse inter-
leukin (IL)-2 complexed with different anti-IL2
monoclonal antibodies ( mAbs) could selectively activate
or inhibit certain lymphogenous populations. Interest-
ingly, 1 of these complexes (IL-2/JES6-1A12 mAb) effi-
ciently expanded CD41 CD251 Tregs. To address the
application of these cells in facilitating allogeneic hema-
topoietic and progenitor cell engraftment following
HCT, IL-2 complexed with anti-IL 2 mAb [17] was785
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compatibility complex (MHC)-matched allogeneic
HCT. Strikingly, this protocol induced transient activa-
tion and expansion of host Tregs accompanied by rapid
and significant early chimerism followed by stable,
long-term donor cell engraftment. Notably, a post-
HCT regimen utilizing 2 injections of IL-2 and anti-IL
2 antibody (IAC) was sufficient to inhibit the emergence
ofhostTcells reactive todonorminorhistocompatibility
transplant antigens [18,19]. The present results demon-
strate that the in situ activation of host Tregs early fol-
lowing allogeneic MHC-matched, minor transplan-
tation antigen (MiHA) mismatched HCT can regulate
host-versus-graft (HVG) responses to support hemato-
poietic progenitor cell engraftment. These findings raise
the possibility for considering clinical approaches toma-
nipulate endogenous Tregs in situ to facilitate engraft-
mentofmarrowallografts and the inductionof tolerance.MATERIALS AND METHODS
Mice
Allmicewere used at 8 to 10weeks of age.C57BL/6
(B6, H-2b) and 129P3/J (H-2b) were purchased from
The Jackson Laboratory (Bar Harbor, ME). BALB.B
(H-2b)mice are bred andmaintained at theUMAnimal
Facility. All experimental procedures were performed
in compliance with the UM Division of Veterinary
Resources guidelines.Bone Marrow Transplant and IAC
Administration
B6 mice were nonablatively conditioned (5.5 Gy
total body irradiation [TBI]). Donor bone marrow
cells from sex-matched BALB.B or 129P3/J were
obtained from femurs and tibia. A single-cell suspen-
sion of the bone marrow cells was prepared by flushing
with a 21-gauge needle and the cells filtered through
a 100-m nylonmesh.Donormarrow cells thus obtained
were then depleted of T cells via complement-medi-
ated lysis using a mixture of T cell-specific antibodies
(H0-13-4 hybridoma supernatant, mouse anti-Thy1.2
IgM, ATCC, Rockville, MD; GK1.5, rat IgG2b
ascites, mouse anti-CD4, generously provided by
Dr. Bruce Blazar, University of Minnesota) and rabbit
complement (Cedarlane Laboratories, Burlington,
NC). The marrow cells were incubated at 37C for
45 minutes, washed twice in Roswell Park Memorial
Institute medium (RPMI), and resuspended for
HCT. Marrow T cell depletion was routinely .99%.
Recipient mice were transplanted (day 0) with T cell-
depleted bone marrow (TCD-BM, 4  106) by tail
vein (i.v.) injection.
IAC was prepared using recombinant murine (rm)
IL-2 with the anti-IL2 mAb (clone JES6-1A12), bothreagents purchased from e-Bioscience (San Diego,
CA). The reagents were incubated at a molar ratio of
2 to 1 (1mg IL-2 and 5 mg Ab) for 15 minutes at room
temperature (RT) as previously described [17]. The re-
sulting IAC was injected into each mouse intraperito-
neally in 500 mL phosphate-buffered saline (PBS)
immediately after preparation. IAC administration
was performed prior to (days25 and23) or following
(days 13 and 15) allogeneic HCT.
Flow Cytometric Analyses
The following antibodies were used for flow
cytometry: Fluorescein isothiocyanate (FITC) or
cychrome-conjugated anti-B220, biotinylated anti
Ly9.1, PE-conjugated streptavidin, FITC labeled
anti-CD4 and CD8, FITC-conjugated Ki-67 (all
antibodies were purchased from BD Pharmingen,
San Diego, CA) and FITC-conjugated FoxP3 (e-
Bioscience). Blood was collected from recipient
mice by retro-orbital bleeding. In some experiments,
complete blood counts (CBC) were performed using
a Hemavet 950 Cell Counter (Drew Scientific,
Waterbury, CT) to compute absolute numbers (cell
numbers/100 mL blood) of circulating FoxP31
CD41CD251T cells. Red cells were lysed using am-
monium chloride lysis buffer (ACK). Lysed cells were
washed twice in staining buffer and stained with the
appropriate antibody or tetramer reagents. The tetra-
mer H60 (Kb/LTFNYRNL, NIH Tetramer Facility)
was used to stain cells as described with minor mod-
ification [18]. Briefly, recipient blood was collected in
heparinized tubes, lysed with ACK buffer, and incu-
bated at RT for 15 minutes together with cychrome
anti-CD8 mAb. The cells were analyzed with the
LSR-1 cytometer (Becton Dickinson, San Jose, CA).
We sought to determine if IAC-treated hosts are
tolerant to donor antigens and whether or not re-
encounter with donor antigens post-HCT would
induce host antidonor CD8T cells detectable by H60
tetramer staining. In some experiments, previously
transplanted B6 mice that were subsequently chime-
ric or nonchimeric were injected i.p. with 2  107
BALB.B splenocytes to compare responses to donor
antigen in these 2 groups. Analysis of circulating
host antidonor CD8 cells was then performed using
H60 tetramer staining between 1 and 3 weeks follow-
ing donor splenocyte injection.
Cell Culture
In some experiments, splenocytes were prepared
from splenic fragments obtained by partial splenec-
tomy of IAC-treated or control recipients of BALB.B
T cell-depleted bone marrow. Briefly, a laparotomy
was performed under general anesthesia using 2%
Avertin. A small fragment of the spleen was excised
and hemostasis achieved by thermocautery. The
Biol Blood Marrow Transplant 15:785-794, 2009 787In Situ Activation and Expansion of Host Tregsabdominal muscle incision was closed with 6-0 silk. A
single-cell suspension was prepared from these splenic
fragments and cultured in RPMI 1640medium supple-
mented with 10% fetal bovine serum (FBS), penicillin/
streptomycin, L-glutamine and 2-ME (Gibco, Grand
Island, NY). Cells (2.5  105/well) were cultured in
quadruplicate in 96-well flat-bottom plates in the pres-
ence of 1 mg/mL lipopolysaccharide (LPS) (Sigma, St.
Louis, MO) or anti-CD3 mAb (Clone 145-2C-11,
20% v/v culture supernatant). Following 3 days of cul-
ture, cells were pulsed with tritiated thymidine for 6
hours, harvested, and cpm obtained using a Filtermate
Harvester (Perkin Elmer, Turku, Finland).
Treg Cell Enrichment
Treg cell enrichment was performed as described
[14,16], with some modifications. Briefly, pooled
lymph node and spleen single cell suspensions from
IAC or PBS-treated mice were first incubated with
an anti-CD8 cell antibody (H02.2 hybridoma superna-
tant), washed, and ‘‘panned’’ on Petri dishes coated
with goat antimouse IgG/IgM (Chemicon Interna-
tional/Millipore, Billerica, MA) to respectively deplete
CD8 and B cells. Cells were then coated with PE-con-
jugated anti-CD25 mAb (PC61, BD Pharmingen) fol-
lowed by anti-PEmagnetic beads for positive selection
of CD41CD251 cells on amagnetic column (Miltenyi
Biotech, Auburn, CA). This procedure routinely
yielded CD41 CD251 cells with .95% purity (these
cells comprised .99% of total CD4 cells).
Statistical Analysis
The statistical significance of outcome parameters
(frequencies, numbers, mean fluorescence intensity
[MFI] values) between experimental and control
groups was evaluated by a standard 2-tailed, unpaired
student t-test (95% confidence) usingGraphpad Prism
4 software.RESULTS
We initially investigated the capacity of IAC treat-
ment to induce the proliferation of CD41CD251 cells
in normal mice based upon the observations reported
by Boyman et al. [17]. Highly enriched CD41
CD251 Tregs (.95% enriched) were prepared from
129P3/J mice 2 days following the second IAC injec-
tion or from PBS control (Figure 1A) mice were 3H-
TdR pulsed for 4 hours and examined for incorpora-
tion. These populations expressed comparable levels
of FoxP3. Tregs from IAC-treated mice exhibited sig-
nificantly higher levels of 3H-TdR incorporation com-
pared to unmanipulated Tregs (Figure 1B). These
observations are consistent with the activation and
proliferation of Tregs following IAC treatment, but
do not exclude a contribution by FoxP32 cells to thisproliferation. Because IAC treatment utilizing
JES6-1A12 mAb preferentially expands Tregs bearing
high affinity IL-2 receptors [17], we next hypothesized
that following their exposure to IAC, the selective ex-
pansion/activation of these cells would enhance their
response to IL-2. In an independent experiment, per-
formed 1 day following a single IAC treatment or
PBS, purified CD41 CD251 Tregs from 129P3/J
mice were cultured in the presence of rmIL-2 and as-
sessed for 3HTdR incorporation. Tregs from IAC-
treated mice incorporated significantly higher levels
of tritiated thymidine compared to those obtained
from PBS-treated controls (Figure 1C). These find-
ings illustrate the capacity of IL-2 to expand Tregs
in vitro following a single in vivo IAC administration.
To further examine the enhanced responsiveness of
Treg cells from IAC-treatedmice to IL-2 induced pro-
liferation, an experiment examined varying doses of
rmIL-2 (Figure 1D). Results indicated that at each
dose of cytokine examined, Tregs from IAC-treated
mice exhibited enhanced proliferation.
Based on our and others previous findings demon-
strating recipient Treg cell presence in B6 recipients
following HCT [16,20], we next investigated the
capacity of IAC to stimulate Treg cells in mice follow-
ing reduced intensity conditioning (RIC) and HCT.
We administered IAC at days 3 and 5 post-HCT. No-
tably, a significant upregulation of surface CD25 ex-
pression was also observed (Figure 2A) consistent with
the in situ activation of these cells following IAC treat-
ment. To examine the kinetics of CD25 upregulation,
MFI was analyzed at 7, 9, and 11 days post-HCT
(Figure 2B). Results indicated the transient nature of
in situ Treg CD25 upregulation. Analysis of circulating
Tregs 1 week post-HCT, that is, 2 days following the
second IAC injection, clearly demonstrated a significant
increase in the numbers of circulating host CD41
CD251FoxP31Tregs in treated recipients versus levels
in PBS-treated control mice (Figure 2C). Notably, the
numbers of Treg cells in IAC-treated, conditioned,
and transplanted recipients were comparable to the cir-
culating numbers in normal, unconditioned B6 mice
(Figure 2C). Tregs in IAC-treated hosts constituted
.40% of total peripheral blood CD41 cells, represent-
ing a .2-fold percentage increase of circulating Tregs
over control mice (data not shown). These observations
regarding activation in recipient peripheral blood lym-
phocytes (PBL) were recapitulated in the spleen 1
week post-HCT (Figure 3A, IAC treated). Further-
more, the intracellular expression of Ki-67 was
enhanced in splenic FoxP31 Tregs of IAC-treated
recipients versus PBS control mice (Figure 3B, IAC
treated), indicating that host Tregs exposed to IAC en-
tered the cell cycle andwere actively proliferating in this
compartment. To determine if more frequent or earlier
IAC injection could enhance these observations, recipi-
ents were injected at days 1, 3, 5, and 6 post-HCT (data
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Figure 1. IAC administration induces in vivo activation of Tregs from normal mice and enhances their ability to proliferate in response to rmIL-2 ex vivo.
(A) Tregs were purified (.95% pure) from spleens and LN of normal 129P3/J mice 2 days after the second infusion with IAC or PBS (n5 2 mice/group)
and analyzed for CD25 (dot plots) and FoxP3 expression (histograms), the latter on gated CD41 CD251 cells. Dot plots: numbers in parentheses rep-
resent mean fluorescence intensity (MFI). (B) Two days after the second IAC injection, 5  104 purified Tregs from the experiment in Figure 1A were
plated in quadruplicate and pulsed with 3H-TdR for 4 hours. (C) In an independent experiment, Tregs from IACmice exhibit enhanced responsiveness to
IL-2 ex vivo. Normal 129P3/J mice were administered a single injection of IAC or PBS (n5 2 mice/group). Tregs were purified (.95% pure) 1 day later;
the cells cultured in the presence of 100 ng rmIL-2 for 72 hours and pulsed with tritiated thymidine for 4 hours. (D) Tregs from IAC-treated mice exhibit
enhanced sensitivity to rmIL-2 ex vivo. Purified Tregs were obtained from 129P3/J mice treated with IAC or PBS as described in part C. These Tregs were
then cultured (4 105/well) in quadruplicate in the presence of the indicated concentrations of rmIL-2. After 72 hours of culture, the cells were pulsed
with 3H-TdR for 6 hours.
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CD251 CD4 T cells or the levels of CD25 expression
were observed. Thus, all subsequent experiments in-
volving IAC post-HCT utilized the 2 injection (ie,
days 13 and 15) regimen.
One potential consequence of the increased number
of host Treg cells after RIC and HCT could be regula-
tion of host antidonor responses that inhibit engraft-
ment. Peripheral blood was, therefore, analyzed for
the presence of circulating donor (Ly9.11, CD19,
CD4/CD8, and granulocyte) cells in MHC-matched
MiHA mismatched recipients following RIC and
TCD-HCT (5.5 Gy TBI) in BALB.B or 129P3/J/
B6 HCT models [19]. As early as 1 week post-BALB.B
(or 129P3/J data not shown) transplant into B6 recipi-
ents, a dramatic and significant increase in the percent
peripheral lymphogenous donor cells was present in re-
cipients treated with IAC afterHCT (days13,15) ver-
sus recipients treated with IAC pre-HCT (days25,23)
or in PBS-treated controls (Figure 4A). In recipients
treated with IAC post-HCT, the levels of peripheral
donor chimerism underwent a rapid increase over thenext 3 weeks and persisted for .6 months post-HCT
(Figure 4B and inset). As noted above,we again observed
no significant differences at this time in the levels of do-
nor chimerism between mice receiving 2 versus 4 IAC
injections during the first week post-HCT (data not
shown). During the later intervals (6 months) post-
HCT, significant levels of myelogenous (Ly6G1) as
well as lymphogenous cells (CD191 and CD4/CD81,
NK1.11) were readily detectable in IAC-treated recipi-
ents, consistent with stable multilineage reconstitution
in recipients with donor cells (Figure 4C).
These observations were consistent with the hypoth-
esis of hostTreg suppression ofHVG.To address this is-
sue, BALB.B TCD-BM cells were administered to RIC
B6 recipients followed by IAC at days 13 and 15. The
H60 tetramer detects TCRs on B6 host CD8 cells that
are reactive to theMiHA immunodominantH60 peptide
expressed in donor BALB.B and 129P3/J hematopoietic
lymphoid cells [18,19,21]. The presence of these CD8
tetramer1 cells becomes readily detectable at 2 to 3weeks
post-HCT in unmanipulated, RIC B6 recipients of
BALB.B or 129P3/J TCD-BM (Figure 5) [19]. In
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Figrue 2. IAC induces transient upregulation of CD25 and expansion of host Tregs following MHC-matched HCT. (A) B6 (H-2b) mice were nonabla-
tively conditioned (5.5 Gy TBI) and 24 hours later transplanted with 4  106 129P3/J B6 (H-2b) T cell-depleted bone marrow (day 0). Three and 5 days
post-HCT, recipient mice were administered IAC i.p. At 1 week post-HCT, circulating PBL were analyzed for CD25 expression on CD41 cells, repre-
sented by MFI (results represent MFI values 6 SEM; n 5 3 mice/group, 3 independent experiments). (B) In an independent experiment, B6 mice were
conditioned and transplanted with 129P3/J as described in Figure 1A. IAC or PBS was infused at days13 and15. At the indicated intervals, post-HCT,
PBL were analyzed for CD25 MFI on CD41 cells (*P\.05; n5 3 mice/group). Data presented as MFI6 SEM. Data points without error bars indicate
SEM values within symbols. IAC induced rapid and transient activation of host Treg cells. (C) B6 mice conditioned with 5.5 Gy TBI and transplanted with
4 106 BALB.B TCD-BMwere infused with IAC or PBS at days13 and15. Recipient mice or normal B6 PBL were then analyzed for circulating CD41
CD251 FoxP31 cells (gated onmononuclear cells) at 1 week post-HCT. Results represent mean cell counts/100 mL6 SEM (n5 3 pools of 2 mice/group;
normal B6 control mice: n 5 4 mice/group, individual data points analyzed). IAC infusion resulted in marked expansion of circulating host Treg popu-
lations post-HCT.
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reduction (P\ .02) in the frequency of these CD81 T
cells in recipients treated with IAC post-HCT compared
to both recipients treated with IAC pre-HCT (data not
shown) and to control, PBS-treated B6 recipients
(Figure 5A). These observations indicate that the
response of donor-specific host CD8 cells following
encounterwithdonorMiHAwas suppressed in recipients
treated with IAC post-HCT as illustrated by their failure
to expand early post-HCT. Notably, a consistent obser-
vation was that in recipients with detectable levels of tet-
ramer binding CD8 T cells at 2 to 3 weeks post-HCT,
there was an absence of peripheral donor chimerism.
Following the initial response of host CD8 T
cells to donor antigens in the marrow allograft de-
tected by H60 tetramer staining, the frequency of
these cells decline to barely detectable levels (data
not shown and [18]). However, upon reactivation
with BALB.B antigens, host antidonor CD8 cell pop-
ulations are induced to expand and the elevated levels
following subsequent reactivation are sustained for
long periods [18]. We next hypothesized that chime-
ric, IAC-treated B6 recipients of donor marrow
allograft would be tolerant to donor antigens, and,therefore, would be unresponsive to challenge with
donor spleen cells. In contrast, PBS-treated B6 mice
that eliminated donor allografts should respond to
donor antigens upon reactivation with donor spleno-
cytes. BALB.B splenocytes (2  107) were adminis-
tered to IAC-treated or PBS-treated B6 recipients
of BALB.B bone marrow 27 weeks post-HCT, and
the frequency of circulating host tetramer1 CD8 cells
analyzed in these mice (Figure 6). One to 3 weeks fol-
lowing BALB.B splenocyte challenge, the frequency
of circulating host tetramer1 CD8 T cells was found
to be markedly elevated in PBS-treated B6 control
recipients, but barely detectable in the chimeric re-
cipients (Figure 6A and B). This in vivo response by
PBS-treated recipients indicates the immunologic ca-
pacity of these animals to respond to donor antigen
challenge. However, the lack of the anti-H60 CD8
T cell response by chimeric, IAC-treated mice could
be a result of either a specific or a more global unre-
sponsive state. To distinguish between these possibil-
ities, partial splenectomies were performed in IAC
and control recipients 7 months post-HCT, and
splenocytes were cultured in the presence of LPS or
anti-CD3 mAb. Responses to LPS (Figure 6C) and
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rable (P . .05) regardless of whether the animals had
or had not engrafted with donor hematopoietic cells.
These findings demonstrate that, although engrafted
animals fail to respond to donor transplantation anti-
gens (ie, H60), they are not globally immunodefi-
cient, and thus support the notion that tolerance to
donor MiHA is present in these IAC-treated recipi-
ents.DISCUSSION
The present studies demonstrate for the first time
that the administration of IL-2 and anti-IL2 mAb
complex post-HCT was highly efficient in the facili-
tation of hematopoietic cell engraftment following
MHC-matched allogeneic HCT in RIC recipients.
The protocol employed consistently induced signifi-
cant expansion and activation of circulating host
Tregs as assessed by the elevated numbers and fre-quency of these cells, their upregulation of CD25,
thymidine incorporation, and Ki-67 expression fol-
lowing IAC administration. Together with the find-
ing that following IAC infusion, expansion of host
antidonor alloantigen reactive CD8 T cells was not
observed, we hypothesize that stimulation of host
Tregs inhibits HVG to support donor hematopoietic
cell engraftment.
A number of laboratories have reported the ability
of cotransplanted donor Treg cell populations tomod-
ulate GVHD and facilitate engraftment [13,14,22].
The rationale underlying such studies was the supposi-
tion that activated Treg cells can inhibit alloreactive T
cell responses, which complicate such transplants.
Treg cells of host origin have been less well explored;
however, unmanipulated Tregs of host origin do not
appear to readily enhance chimerism following alloge-
neic HCT [6,23]. Recent studies by Boyman and col-
leagues [17] reported the capacity of IL-2/anti-IL2
mAb conjugates to expand CD41CD251 T cells in
situ in normal mice. We, therefore, sought to
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Figure 4. Administration of IAC post-HCT enhances early and stable long-term peripheral donor (Ly9.11) chimerism. B6 mice were sublethally
irradiated (5.5 Gy TBI) and injected with IAC pre-HCT (days 25 and 23) or post-HCT (days 13 and 15). Recipient mice received 4  106 BALB.B
TCD-BM (day 0). Peripheral donor cell (Ly9.11) frequency was assessed by staining recipient PBL with Ly9.1 at 1 week (A, left) and 27 weeks (A,
right) post-HCT. No lethality was observed in any group in this experiment. (B) Kinetics of donor chimerism in the BALB.B/ B6 experiment de-
scribed in part A following RIC, HCT, and pre-HCTor post-HCT IAC administration. Inset represents the rapid increase in donor chimerism levels in
IAC-infused recipients during the initial 3 weeks post-HCT. (C) Representative dot plots of recipient PBL stained for Ly9.1, CD19, CD4/CD8, and
NK1.1 gated on mononuclear cells and Ly6G gated on total donor cells in IAC-treated (top panels) or PBS-treated (bottom panels) control hosts.
Data represent dot plots from individual B6 animals 21 weeks post-HCTwith BALB.B TCD-BM as described above. Experiments presented above
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donor chimerism at .5 months post-transplant.
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cells in HCT recipients using IAC injection as a strat-
egy to regulateHVGalloreactiveT cell responses to fa-
cilitate hematopoietic engraftment. Observations in
RIC animals demonstrated that host Treg cells present
could, in fact, be efficiently stimulated by 1 or 2 IAC in-
jections evidenced by enhanced CD25 expression as
well as proliferative activity by these cells (Figures
1-3). Thus, similar to Tregs in normal mice (Figure 1),
these findings show that residual host Treg cells, pres-
ent following RIC and transplant [16,20], could be ac-
tivated and expanded in situ by systemic administration
of IAC. The efficacy of the IAC protocol employed
here was evidenced by the finding that the numbers
of circulatingTregs in complex infusedHCTB6 recip-
ients early posttransplant were indistinguishable from
Treg numbers in normal, unconditioned, nontrans-
planted B6 mice.
We then examined the consequence of these IAC
activated host Tregs on hematopoietic outcome fol-
lowing transplant of T CD, MHC-matched MiHA
mismatched marrow. Our studies clearly illustrate
consistent and dramatic enhancement of donor chime-rism in RIC hosts followingMHC-matched allogeneic
HCT and IAC treatment post-HCT. Notably, the
early enhanced levels of circulating donor hematopoi-
etic cells in such recipients persisted long term, as evi-
denced by donor chimerism .6 months post-HCT.
These observations demonstrate that hematopoietic
donor lymphogenous and myelogenous progenitor
cell engraftment took place following treatment with
IAC post-HCT. Notably, in these studies, the timing
of IAC administration was found to be crucial in en-
hancing initial donor chimerism and prolonging allo-
geneic marrow engraftment post-HCT. We propose
that early (1-2 weeks) post-HCT, the activation of
host Tregs following IAC administration enhances
their capacity to suppress host anti-donor CD8 T cell
responses that mediate resistance to engraftment in
this MHC-matched HCT model. The consistent ab-
sence of detectable peripheral H60 tetramer binding
CD8 cells 2 to 3 weeks post-HCT in IAC-treated mar-
row allograft recipients indicated that there was signif-
icant inhibition of the initial activation and expansion
of these host effector CD8 T cells. These findings are
consistent with the notion that the suppression of
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Figure 5. Administration of IAC post-HCT suppresses the emergence and early expansion of host antidonor CD8 T cells. PBL from the indicated IAC
treatment groups (n5 9 for IAC; n5 8 for PBS) were stained with the H60 tetramer 2 weeks post-HCT. The frequency of circulating tetramer-binding
cells is expressed as tetramer1 CD8 cells as % of gated mononuclear cells (A) *P\.02 (IAC-treated versus PBS-treated control recipients). (B) Rep-
resentative dot plots for H60 staining obtained from IAC-treated and PBS-treated B6 recipients of BALB.B bone marrow.
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lying the enhancement of donor chimerism. Ex vivo,
Tregs have been shown to efficiently regulate CD8 T
cell responses by suppressing proliferation and inte-
feron (IFN)g production induced by antigen or poly-
clonal stimulation [24].
A recent study reported that the adoptive transfer of
ex vivo activated Tregs of host origin, induced antigen-
specific tolerance to donor marrow in MHC-mis-
matched HCT [13]. The findings reported here sug-
gest that the strategy of 2 injections of IAC
post-HCT may be sufficient to induce tolerance to
donor antigens in the MHC-matched, MiHA0 1 2 3 4
0
3
6
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Figure 6. Chimeric, IAC-treated B6 recipients of BALB.B marrow are tolerant
(n5 3/group) were injected with 2 107 BALB.B splenocytes at 27 weeks post
CD8 cells. Results are presented as the average % tetramer-positive cells of to
tetramer (PE) CD8 staining (cychrome) cells from each group is shown. (C, D
cipients of BALB.B marrow is not associated with inhibition of host responses
mice were partially splenectomized at7months post-HCTand splenocytes cu
hours, and then pulsed with 3HTdR for 6 hours.mismatched model. As mentioned above, the
inhibition of the expansion of host antidonor reactive
CD8 T cells was apparent within several weeks post-
transplant using this regimen. Importantly, assessment
for these antidonor alloreactive T cells months later in
transplanted mice indicated that although they were
readily induced by introducing donor alloantigen bear-
ing cells in non-IAC, that is, nonchimeric recipients
(that had previously rejected the donor marrow allo-
graft), our attempts to elicit their ‘‘reemergence’’ in
IAC-treated chimeric recipients were unsuccessful
(Figure 6). The capacity of both chimeric and nonchi-
meric recipients to respond equivalently to anti-CD3IAC
IAC + Media
PBS
PBS + Media
αCD3
CD8
0.040.4
13.6 8.1
PBS IAC
to donor antigens 21 weeks post-HCT. B6 mice treated with IAC or PBS
-HCT. (A) One to 3 weeks later, PBL were analyzed for tetramer-binding
tal CD8 cells from 3 individual mice. (B) Representative dot plot of H60
) Suppression of host antidonor responses in chimeric, IAC-treated re-
to LPS and anti-CD3 activation. Post-HCT IAC-treated or PBS-treated
ltured in quadruplicate in the presence of LPS (C) or anti-CD3 (D) for 72
Biol Blood Marrow Transplant 15:785-794, 2009 793In Situ Activation and Expansion of Host TregsmAb and LPS stimulation ruled out global immunode-
ficiency in chimeric animals and further supports the
notion that tolerance to donor alloantigens is present
in these posttransplant IAC-treated recipients.We con-
clude that treatment with IAC post-HCT resulted in
efficient host reconstitution with donor-derived alloge-
neic hematopoietic cells, and speculate that central tol-
erance contributes to the pattern of responses we
observed.
Together, the findings in our study plausibly demon-
strate for the first time that a brief, timely in vivo IAC
regimen inRIC recipients ofMHC-matchedmarrow al-
lografts leads to enhanced and stable, long-term donor
chimerism. Suppression of host antidonor responses in
IAC-treatedmice early post-HCT is consistentwith reg-
ulation, that is, inhibition of the barrier to engraftment
shortly after transplant as evidenced by the failure of
host antidonor CD8 T cells to emerge during the first
4 weeks post-HCT. Thus, the strategy employing IAC
in our preclinical MHC-matched allogeneic HCT may
support the use of this treatment for enhancing marrow
progenitor engraftment and tolerance induction in se-
lected clinicalMiHA-mismatched allogeneicmarrow re-
cipients. Notably, following their in vivo activation by
IAC, Tregs were rendered more sensitive to IL-2 driven
ex vivo proliferation and expansion (Figure 1). These
findings suggest that in vivo, a single IAC treatment fol-
lowed by IL-2 may be sufficient to achieve equivalent
levels of chimerism as observed by the multiple IAC
treatments used here. IL-2 has been examined in TCR
experimental bone marrow transplant (BMT) and has
been effectively used in the clinic for therapy [25-27]. Re-
cent studies have reported that such cytokine therapy can
result in increased numbers of Treg cells in clinical and
experimental disorders [28-32]. Treg expansion induced
by IAC could, therefore, be considered to increase the
numbers of Tregs targeted by IL-2 in the settings of au-
toimmunedisease and transplantation to further their ac-
tivation and expansion. This strategy would minimize
the use of cytokine-antibody complex, thus reducing
the risk of immune complex disease.ACKNOWLEDGMENTS
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